ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!IPHA Company Profile and Key Details
Innate Pharma S.A.
IPHA Stock Price Chart
Stock Price Today
Innate Pharma S.A. (IPHA) stock declined over -2.43%, trading at $2.21 on NASDAQ, down from the previous close of $2.26. The stock opened at $2.07, fluctuating between $2.17 and $2.25 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
Company Information
| Employees | 168 |
| Beta | 0.79 |
| Sales or Revenue | $51.90M |
| 5Y Sales Change% | -0.525% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Innate Pharma S.A. (NASDAQ: IPHA) stock price is $2.21 in the last trading session. During the trading session, IPHA stock reached the peak price of $2.25 while $2.17 was the lowest point it dropped to. The percentage change in IPHA stock occurred in the recent session was -2.43% while the dollar amount for the price change in IPHA stock was -$0.06.
The NASDAQ listed IPHA is part of Biotechnology industry that operates in the broader Healthcare sector. Innate Pharma S.A. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. François Romagné Ph.D.
Founder
Mr. Alessandro Moretta M.D., Ph.D.
Founder
Dr. Mondher Mahjoubi M.D.
Chairman of Executive Board & Chief Executive Officer
Dr. Herve Brailly
Co-Founder & Chairman of Supervisory Board
Mr. Eric Vivier D.V.M., M.B.A., Ph.D.
Founder, Senior Vice President & Chief Scientific Officer
Dr. Marc Bonneville Ph.D.
Founder
Mr. Frederic Lombard M.B.A.
Senior Vice President & Chief Financial Officer
Ms. Odile Belzunce
Vice President of Compliance & Operations
Mr. Jean Jacques Fournié Ph.D.
Founder
Mr. Yannis Morel Ph.D.
Executive Vice President of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board
IPHA's closing price is 75.19% higher than its 52-week low of $1.29 where as its distance from 52-week high of $3.51 is -35.63%.
Number of IPHA employees currently stands at 168.
Official Website of IPHA is: https://www.innate-pharma.com
IPHA could be contacted at phone 334 303 03030 and can also be accessed through its website. IPHA operates from 117, Avenue de Luminy, Marseille, 13009, France.
IPHA stock volume for the day was 99.28K shares. The average number of IPHA shares traded daily for last 3 months was 731.24K.
The market value of IPHA currently stands at $184.80M with its latest stock price at $2.21 and 83.81M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com